Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer
Overview of attention for article published in Gynecologic Oncology, September 2010
Altmetric Attention Score: 6
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
Good Attention Score compared to outputs of the same age (71st percentile)
-
Good Attention Score compared to outputs of the same age and source (73rd percentile)
Readers on
- mendeley
- 46 Mendeley